The role of adipokines in the disease of metabolic-associated fatty liver disease

According to the World Health Organization’s reports, the prevalence of fatty liver disease is increasing worldwide, and that of type 2 diabetes in adults aged over 18 years has increased from 4.7% in the 1980s to 8.5% in 2014. Metabolic (dysfunction)-associated fatty liver disease (MAFLD) does not only affect the liver but also poses as a serious threat to the entire body, with approximately 25% of the patients have cardiovascular diseases, which are aging-associated health issues. This literature review obtained data from databases such as Cochrane Library, PubMed or Medline, UpToDate, and Google Scholar, using terms from Medical Subject Headings for keywords such as adipokines, digestive disease, MAFLD, microbiota, and microbiome. Articles on the molecular biological mechanism would be included, along with case–control studies, systematic review and meta-analysis, analytical research, and randomized control studies, to explore the effect of adipokines or myokines on MAFLD epidemiology and prevention. Thus, this article describes the adipokines and its function related to MAFLD.